Literature DB >> 10552007

Hemolytic uremic syndrome in small-bowel transplant recipients: the first two case reports.

A Humar1, J Jessurun, H L Sharp, R W Gruessner.   

Abstract

Post-transplant hemolytic uremic syndrome (HUS) is an uncommon but well-described complication in solid organ transplant recipients. Believed to be secondary to immunosuppressive therapy, it has been reported after kidney, liver, pancreas, heart, and lung transplants. In all reported cases, the primary organ affected was the kidney (transplant or native). But until now, no cases after small-bowel transplants and no cases in which the kidney was not the primary organ affected have been reported. We report two cases of HUS in small-bowel transplant recipients. In our first case, clinical presentation was with renal failure; biopsy of the native kidney demonstrated the typical histological changes seen with HUS, namely occlusion of the microcirculation by thrombi and platelet aggregation. Immunosuppression was changed from tacrolimus to cyclosporin, but with no improvement in renal function. In our second case, the transplanted bowel was the primary organ affected. This recipient presented with ulcers in the bowel mucosa, which were believed to be ischemic in origin, secondary to occlusive vascular lesions affecting the small vessels in the transplanted bowel. Her tacrolimus dose was decreased with resolution of ulcers and no evidence of rejection. These two cases represent the first reports of HUS after small-bowel transplants; in addition, our second case represents the first report of an extrarenal graft as the primary organ affected. When caring for small-bowel transplant recipients, physicians must be alert to the possibility of HUS and its various presentations.

Entities:  

Mesh:

Year:  1999        PMID: 10552007     DOI: 10.1007/s001470050245

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  4 in total

1.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Thrombotic microangiopathy-like disorder after living-donor liver transplantation: a single-center experience in Japan.

Authors:  Tomohide Hori; Toshimi Kaido; Fumitaka Oike; Yasuhiro Ogura; Kohei Ogawa; Yukihide Yonekawa; Koichiro Hata; Yoshiya Kawaguchi; Mikiko Ueda; Akira Mori; Hajime Segawa; Kimiko Yurugi; Yasutsugu Takada; Hiroto Egawa; Atsushi Yoshizawa; Takuma Kato; Kanako Saito; Linan Wang; Mie Torii; Feng Chen; Ann-Marie T Baine; Lindsay B Gardner; Shinji Uemoto
Journal:  World J Gastroenterol       Date:  2011-04-14       Impact factor: 5.742

3.  Thrombotic microangiopathy developing in early stage after renal transplantation with a high trough level of tacrolimus.

Authors:  Mitsuru Saito; Shigeru Satoh; Hideaki Kagaya; Hiroshi Tsuruta; Takashi Obara; Teruaki Kumazawa; Takamitsu Inoue; Kazuyuki Inoue; Masatomo Miura; Takeshi Yuasa; Atsushi Komatsuda; Norihiko Tsuchiya; Tomonori Habuchi
Journal:  Clin Exp Nephrol       Date:  2008-02-08       Impact factor: 2.801

Review 4.  Intestinal transplantation in children: a review of immunotherapy regimens.

Authors:  Navdeep S Nayyar; William McGhee; Dolly Martin; Rakesh Sindhi; Kyle Soltys; Geoffrey Bond; George V Mazariegos
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.